Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2012

01-06-2012

Fractalkine Upregulates Inflammation through CX3CR1 and the Jak–Stat Pathway in Severe Acute Pancreatitis Rat Model

Authors: Li-ya Huang, Ping Chen, Ling-xiao Xu, Yu-fen Zhou, Yong-ping Zhang, Yao-zong Yuan

Published in: Inflammation | Issue 3/2012

Login to get access

Abstract

Based on the function of chemokine fractalkine (FKN), acting as both adhesion and chemoattractant, FKN plays a role in acute inflammatory response. In this study, we investigated the mechanism of FKN mediated upregulation inflammation in severe acute pancreatitis (SAP) rat models. Western blot, reverse transcriptase-polymerase chain reaction, and immunofluorescence demonstrated that FKN and its receptor CX3CR1 were overexpressed in cerulein-stimulated AR42J cells. AG490 and FKN-siRNA inhibited activation of Janus kinase/signal transducers and activators of transcription (Jak/Stat) in cerulein-stimulated AR42J cells. Following exposure AG490 and FKN-siRNA inhibited tumor necrosis factor-alpha expression by enzyme-linked immunosorbent assay and immunohistochemistry in vivo the SAP rat models. These results showed FKN and CX3CR1 were involved inflammatory response in cerulein-stimulated AR42J cells. FKN upregulates inflammation through CX3CR1 and the Jak/Stat pathway in SAP rat models.
Literature
1.
Harrison, D.A., G. D’Amico, and M. Singer. 2007. The Pancreatitis Outcome Prediction (POP) Score: a new prognostic index for patients with severe acute pancreatitis. Critical Care Medicine 35: 1703–1708.PubMedCrossRef
2.
Bazan, J.F., K.B. Bacon, G. Hardiman, et al. 1997. A new class of membrane bound chemokine with a CX3C motif. Nature 385: 640–644.PubMedCrossRef
3.
Volin, M.V., J.M. Woods, M.A. Amin, M.A. Connors, L.A. Harlow, and A.E. Koch. 2001. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. The American Journal of Pathology 159: 1521–1530.PubMedCrossRef
4.
Lee, S.J., S. Namkoong, Y.M. Kim, et al. 2006. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNos-dependent signal pathways. American Journal of Physiology-Heart and Circulatory Physiology 291: H2836–H2846.PubMedCrossRef
5.
Efsen, E., C. Grappone, R.M. DeFranco, et al. 2002. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. Journal of Hepatology 37: 39–47.PubMedCrossRef
6.
Segerer, S., E. Hughes, K.L. Hudkins, M. Mack, T. Goodpaster, and C.E. Alpers. 2002. Expression of the fractalkine receptor (CX3CR1) in human kidney disease. Kidney International 62: 488–495.PubMedCrossRef
7.
8.
Igaz, P., S. Toth, and A. Falus. 2001. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflammation Research 50: 435–441.PubMedCrossRef
9.
Rawlings, J.S., K.M. Rosler, and D.A. Harrison. 2004. The JAK/STAT signaling pathway. Journal of Cell Science 117: 1281–1283.PubMedCrossRef
10.
Levitzki, A., and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782–1788.PubMedCrossRef
11.
Chen, P., Y. Yuan, S. Wang, L. Zhan, and J. Xu. 2006. Captopril, an angiotensin converting enzyme inhibitor, attenuates the severity of acute pancreatitis in rats by reducing expression of matrix metalloproteinase. The Tohoku Journal of Experimental Medicine 209: 99–101.PubMedCrossRef
12.
Yu, J.H., K.H. Kim, and H. Kim. 2006. Suppression of IL-1β expression by the Jak 2 inhibitor AG490 in cerulein-stimulated pancreatic acinar cells. Biochemical Pharmacology 72: 1555–1562.PubMedCrossRef
13.
Grewal, H.P., E.L. Mohey, A. Din, L. Gaber, M. Kotb, and A.O. Gaber. 1994. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-alpha polyclonal antibody. Am. J. Sug 167: 214–218.CrossRef
14.
Zhang, Xi-Ping, J. Zhang, Mei-Li Ma, et al. 2010. Pathological changes at early stage of multiple organ injury in a rat model of severe acute pancreatitis. Hepatobiliary & Pancreatic Diseases International 9: 83–85.
15.
Zhang, Q., K. Shimoya, K. Temma, et al. 2004. Expression of fractalkine in the fallopian tube and of CX3CR1 in sperm. Human Reproduction 19: 409–414.PubMedCrossRef
16.
Ancuta, P., R. Rao, A. Moses, A. Mehle, et al. 2003. Fractalkine preferentially mediates arrest and migration of CD16 monocytes. Journal of Experimental Medicine 197: 1701–1707.PubMedCrossRef
17.
Fraticelli, P., M. Sironi, G. Bianchi, et al. 2001. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. Journal of Clinical Investigation 107: 1173–1181.PubMedCrossRef
18.
Umehara, H., E.T. Bloom, T. Okazaki, Y. Nagano, O. Yoshie, and T. Imai. 2004. Fractalkine in vascular biology: from basic research to clinical disease. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 34–40.PubMedCrossRef
19.
Haskell, C.A., M.D. Cleary, and I.F. Charo. 2000. Unique role of the chemokine domain of fractalkine in cell capture: kinetics of receptor dissociation correlate with cell adhesion. Journal of Biological Chemistry 275: 34183–34189.PubMedCrossRef
20.
Garton, K.J., P.J. Gough, C.P. Blobel, et al. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). Journal of Biological Chemistry 276: 37993–38001.PubMed
21.
Combadiere, C., S. Potteaus, J.L. Gao, et al. 2003. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009–1016.PubMedCrossRef
22.
Eriksson, E.E. 2004. Mechanisms of leukocyte recruitment to atherosclerosclerotic lesions: future prospects. Current Opinion in Lipidology 15: 5911–5918.CrossRef
23.
Duxbury, M.S., E. Matros, H. Ito, M.J. Zinner, S.W. Ashley, and E.E. Whanq. 2004. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Annals of Surgery 240(4): 667–674.PubMed
24.
Filleur, S., A. Courtin, S. Ali, et al. 2003. siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Research 63(14): 3919–3922.PubMed
25.
Sioud, M. 2010. Advances in RNA sensing by the immune system: separation of siRNA unwanted effects from RNA inference. Methods in Molecular Biology 629: 33–52.PubMedCrossRef
26.
Brummelkamp, T.R., R. Bernards, and R. Agami. 2002. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2(3): 243–247.PubMedCrossRef
27.
Chetty, C., P. Bhoopathi, P. Joseph, S. Chittivelu, Js Rao, and S. Lakka. 2006. Adenovirus -mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Molecular Cancer Therapeutics 5(9): 2289–2299.PubMedCrossRef
28.
Kisseleva, T., S. Bhattacharya, J. Braunstein, and C.W. Schindler. 2002. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285: 1–24.PubMedCrossRef
29.
Pelletier, S., F. Duhamel, P. Coulombe, M.R. Popoff, and S. Meloche. 2003. Rho family GTPase are required for activation of Jak/Stat signaling by G protein couple receptors. Molecular and Cellular Biology 23: 1316–1333.PubMedCrossRef
Metadata
Title
Fractalkine Upregulates Inflammation through CX3CR1 and the Jak–Stat Pathway in Severe Acute Pancreatitis Rat Model
Authors
Li-ya Huang
Ping Chen
Ling-xiao Xu
Yu-fen Zhou
Yong-ping Zhang
Yao-zong Yuan
Publication date
01-06-2012
Publisher
Springer US
Published in
Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9406-5

Other articles of this Issue 3/2012

Inflammation 3/2012 Go to the issue

OriginalPaper

Genes Differentially Regulated by NKX2-3 in B Cells Between Ulcerative Colitis and Crohn’s Disease Patients and Possible Involvement of EGR1

OriginalPaper

Effect of HSP65 on the Expression of Adhesion Molecules in Mice Heart Endothelial Cells

OriginalPaper

Anti-inflammation Effects of Corn Silk in a Rat Model of Carrageenin-Induced Pleurisy

OriginalPaper

Mast-Cell-Releasing Tryptase Triggers Acute Lung Injury Induced by Small Intestinal Ischemia–Reperfusion by Activating PAR-2 in Rats

OriginalPaper

Synergism Between Fentanyl and Tramadol in Tonic Inflammatory Pain: the Orofacial Formalin Test

OriginalPaper

Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Mediates p38 Mitogen-Activated Protein Kinase Activation and Signal Transduction in Peripheral Blood Mononuclear Cells from Patients with Lupus Nephritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits